Current medical management largely focuses on controlling the classic motor symptoms of bradykinesia, tremor, rigidity and postural instability1,2.
Dopaminergic pharmacotherapies designed to restore depleted dopamine in the substantia nigra pars compacta are the mainstay of PD treatment and include addition of dopamine precursors, direct activation of dopamine receptors, and prevention of the endogenous dopamine breakdown2.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest